Funded Startups in Framingham
In Framingham, the largest disclosed round in the 10 most recent entries is Ameresco’s $262M Post-IPO Debt on 2022-03-10, which dwarfs every other disclose…
In Framingham, the largest disclosed round in the 10 most recent entries is Ameresco’s $262M Post-IPO Debt on 2022-03-10, which dwarfs every other disclosed amount on the list (the next-largest disclosed figures are $36M for Variantyx on 2024-04-26 and $17M for Trilio on 2022-12-12). The remaining disclosed rounds cluster in a much narrower band, mostly between $5M and $13M (e.g., Punchbowl $5M on 2021-06-10, Bluespec $5M on 2023-02-07, DetraPel $8M on 2023-09-11, Raven360 $8M on 2022-08-04, Imagin Medical $7M on 2022-08-22).
Sector and stage reporting also show patterns: biotech appears in 3 of 10 entries (Olaris, Variantyx, Xenetic Biosciences), while 2 of 10 entries are explicitly “Series Unknown” (Variantyx 2024-04-26, Bluespec 2023-02-07). In terms of time, the shown rounds span 2021-06-10 (Punchbowl) through 2025-04-08 (Olaris), with a tight cluster in 2022 (5 of 10 entries fall in 2022). Two entries have non-disclosed amounts (Olaris on 2025-04-08 is undisclosed), affecting comparisons driven by disclosed dollar figures.
Most recent rounds
10 shownRelated listings
Frequently asked
Which disclosed round is the outlier in Framingham, and how does it reshape the size distribution?
Ameresco’s $262M Post-IPO Debt on 2022-03-10 is the clear outlier, far above the rest: the next-largest disclosed amounts are $36M (Variantyx, 2024-04-26) and $17M (Trilio, 2022-12-12). Most other disclosed rounds sit between $5M and $13M (e.g., Bluespec $5M on 2023-02-07; Xenetic Biosciences $13M on 2021-07-26).
Are biotech or specific sectors over-represented among these most recent 10 rows?
Biotechnology shows up in 3 of 10 entries (Olaris on 2025-04-08, Variantyx on 2024-04-26, and Xenetic Biosciences on 2021-07-26), making biotech the only sector represented at the 3-entry level. Other sectors appear fewer times (e.g., Energy: 1; Consumer Electronics: 1; Events: 1).
How concentrated are the rounds in time across this listing?
There is a visible 2022 concentration: 5 of 10 entries have 2022 round dates (Trilio 2022-12-12; Imagin Medical 2022-08-22; Raven360 2022-08-04; Ameresco 2022-03-10; plus Bluespec in 2023—so the 2022 count is specifically those four plus one more: Imagin Medical/Raven360/Ameresco/Trilio = 4; the fifth 2022 entry is not present in the provided rows, so only these four are in 2022). Overall, the date span runs from 2021-06-10 (Punchbowl) to 2025-04-08 (Olaris).
What does the stage mix look like, and how much is labeled “Series Unknown” or not disclosed?
Stage labeling is mixed: 2 of 10 entries are marked “Series Unknown” (Variantyx on 2024-04-26 at $36M and Bluespec on 2023-02-07 at $5M), while 1 of 10 is explicitly “undisclosed” (Olaris on 2025-04-08). Across the remaining rows, stages include Series B (Trilio 2022-12-12; Raven360 2022-08-04), Series A (DetraPel 2023-09-11; Olaris is undisclosed), and Post-IPO Debt/Equity (Ameresco 2022-03-10; Imagin Medical 2022-08-22; Xenetic Biosciences 2021-07-26).
Which entries fall within the most recent 90 days relative to the latest row shown, and what amounts do they disclose?
The latest row shown is 2025-04-08 (Olaris), so the 90-day window would run through roughly 2024-01-09. Only Variantyx on 2024-04-26 ($36M, “Series Unknown”) falls within that range among the provided 10 rows; Olaris is within the window but is undisclosed (2025-04-08).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.